Mark Barbato, RPh, MBA, President and Chief Executive Officer, is an experienced pharmaceutical executive who had a 35+ year career with Eli Lilly and Company, retiring as Vice President, Alliance Management. He successfully led global product teams overseeing the development, registration, and commercialization of two products (ReoPro® and Cialis®) in partnerships. He is well-integrated into the Indiana life sciences community. Mark has a B.S degree in pharmacy from the University of Minnesota and an MBA degree from Indiana University.
David Nurok, PhD, Chief Scientific Officer and founder, is associate professor emeritus, analytical chemistry and separation science, at Indiana University-Purdue University Indianapolis, and is co-inventor of the instrumental technique that InChromatics will develop. He is the author of several papers in the field of pressurized planar electrochromatography and is co-inventor on the patents pertaining to the technology of PPEC. David has a B.Sc. (Hons) degree in chemistry and a PhD from the University of Cape Town (South Africa), and was a postdoctoral fellow at the University of Houston. Prior to his academic career, he spent 10 years on the industrial side, including the chemical industry as well as at an institute dedicated to the sugar industry.
Jim Schulz is providing Chief Financial Officer and accounting services. He is currently COO at Monon Bioventures, LLC, and is also a partner at Upward Focus, LLC, providing senior level financial and accounting services to emerging companies. Previously, he was CFO at Naurex Inc., a managing director at Milestone Advisors, and director of finance at Suros Surgical Systems, where he implemented operational and financial improvements and assisted in the company’s acquisition by Hologic, Inc. Prior to Suros, Jim served in a number of financial and operational roles at Eli Lilly & Co. He began his career working with a variety of clients as an accountant at Ernst & Young. Jim holds a bachelor’s degree from Indiana University and is a licensed CPA.